Impressive new study results suggest potential new therapeutic use for Nexstim SmartFocus® nTMS in postsurgical rehabilitation of Paresis
17 May 2021
Helsinki, Finland: 17 May 2021 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) announces that a new study published in Brain Stimulation in May reports that the therapeutic use of Nexstim navigated repetitive transcranial magnetic stimulation (nrTMS) significantly improved outcomes for glioma patients suffering from post-surgical paresis. The study suggests that patients who suffer from a severe decline in hand function after brain tumor surgery can be treated post-operatively for 7 days with 15 minutes of nrTMS plus 30 minutes of physiotherapy per day. The study “Navigated repetitive transcranial magnetic stimulation improves the outcome of postsurgical paresis in glioma patients – A randomized, double-blinded trial”, using Nexstim’s NBS System with SmartFocus® nTMS, was published by a neurosurgical team at the Technical University of Munich (TUM) in Germany (1). Further information on Nexstim’s website.